Clinical trials: Triple Negative Breast Cancer (TNBC), Early Setting, open to volunteers
Triple Negative Breast Cancer (TNBC), Early Setting
LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
LESLIE is a multicentric randomized controlled trial in patients with triple negative breast cancer receiving neoadjuvant chemo/immunotherapy (NAT).
- Trial name
- LESLIE (NCT06831955)
- Testing
- Exercise Therapy, Fasting-Mimicking Diet, SOC
- Where
- 10 sites in Belgium
- Volunteers
- 356 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Triple Negative Breast Cancer (TNBC), Early Setting
Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.
CAPTIVATE is a multi-center translational and observational trial, that aims to investigate the impact of the gut microbiome on treatment outcomes in women with untreated, stage I-III Triple Negative undergoing neoadjuvant…
- Trial name
- CAPTIVATE (NCT07551765)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Barts & The London NHS Trust
Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
The phase III, multicenter, pragmatic PLANET trial aims to evaluate the benefit and safety of pembrolizumab as an addition to standard of care adjuvant treatment (capecitabine or olaparib) in triple negative breast cancer (TNBC)…
- Conditions
- Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer, Breast Cancer Stage II
- Trial name
- PLANET (NCT07486687)
- Testing
- Standard of care plus pembrolizumab, Standard of care (capecitabine or olaparib)
- Volunteers
- 1,000 people
- Sponsor
- The Netherlands Cancer Institute